Mass General Brigham, Inc Nurix Therapeutics, Inc. Transaction History
Mass General Brigham, Inc
- $43.6 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
74.4MCall Options Held
56.9KPut Options Held
7.9K-
Black Rock Inc. New York, NY6.82MShares$78.4 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.5MShares$63.2 Million2.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$50.7 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.05MShares$46.6 Million5.06% of portfolio
-
Commodore Capital LP New York, NY3.98MShares$45.7 Million4.63% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $542M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...